TFF3 and medical procedure: Importantly, AMPC exhibited promising efficacy in inhibiting the growth of both the H1975 cell line (with EGFR exon 20 T790M mutation) and the H1299 cell line (with p53 depletion), suggestive of TFF3 inhibition as a potential therapeutic strategy in lung ADC.